MapLight Therapeutics, Inc.
MPLTMapLight Therapeutics, Inc. in brief
MapLight Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Redwood City, California, USA. Its market value was $558 M on 15 September 2026, which makes it the 12,083rd largest listed company in the world and the 2,460th largest in the USA on this site. It employs about 133 people and Christopher A. Kroeger is its chief executive. Its shares trade under the symbol MPLT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About MapLight Therapeutics, Inc.
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. We believe our deep understanding of these causal links between the modulation of defined neural circuits and the resulting changes in disease-specific behaviors will enable us to develop therapeutics that can deliver efficacy, safety, tolerability and ease-of-use advantages to patients and prescribers.
From the company's annual report filed with the US SEC: read the report
MapLight Therapeutics, Inc. timeline
- 2019
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed MapLight Therapeutics, Inc.Formerly Alvarado Therapeutics, Inc..
- 2025
- 🔔· approximateInitial public offering on Nasdaq
Events of MapLight Therapeutics, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,494 (Aug 2026) · #2,458 (Sep 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.2×
- Free cash flow yield
- -24.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -35.2%
- Liabilities / assets
- 4.4%
- Profit per employee
- $-1.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-169M | $-161M | — |
| Dec 2024 | — | — | $-83M | $-78M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-138M | $0M | $-139M | $-18.56 | — |
| Dec 2024 | $-79M | $1M | $-80M | $-105.38 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-60M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Sep 18, 2026S-1/AIPO registration (amended)
- Sep 9, 2026S-1IPO registration
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportMaterial agreement · Results of operations · Unregistered share sale · Regulation FD disclosure
- Jul 27, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 24, 20268-KCurrent reportShareholder vote
- Jun 22, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 18, 20268-KCurrent reportDirectors or officers changed
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 29, 20268-KCurrent reportDirectors or officers changed
- Apr 29, 2026DEF 14AProxy statement
Official filings of MapLight Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-169 M
- Net income
- $-161 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $480 M
- Total liabilities
- $21 M
- Total equity
- $458 M
As of December-2025
Top 98 institutional investors in MapLight Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Fcpm III Services B.V. | 4,428,328 | +1,201,928 (+37.25%) | 10.44% | $45 M | Nov 16, 2026 |
| 2 | Goldman Sachs Group Inc | 3,599,556 | +1,651,244 (+84.75%) | 8.48% | $37 M | Nov 16, 2026 |
| 3 | Nan Fung Group Holdings Ltd | 2,300,328 | +1,329,075 (+136.84%) | 5.42% | $23 M | Nov 13, 2026 |
| 4 | Novo Holdings A/s | 2,086,622 | -1,600,000 (-43.40%) | 4.92% | $21 M | Nov 16, 2026 |
| 5 | BlackRock, Inc. | 1,712,729 | +687,595 (+67.07%) | 4.04% | $17 M | Nov 13, 2026 |
| 6 | FMR LLC | 1,541,940 | +718,384 (+87.23%) | 3.63% | $16 M | Nov 10, 2026 |
| 7 | Deep Track Capital, LP | 1,318,101 | New | 3.11% | $13 M | Nov 16, 2026 |
| 8 | Baker Bros. Advisors LP | 1,166,763 | +802,058 (+219.92%) | 2.75% | $12 M | Nov 16, 2026 |
| 9 | Price T Rowe Associates Inc /MD/ | 1,132,288 | -290,647 (-20.43%) | 2.67% | $12 M | Nov 16, 2026 |
| 10 | T. Rowe Price Investment Management, Inc. | 945,216 | -1,836,512 (-66.02%) | 2.23% | $10 M | Nov 16, 2026 |
| 11 | Sanofi | 912,041 | 0 (0.00%) | 2.15% | $9 M | Nov 5, 2026 |
| 12 | 5AM Venture Management, LLC | 741,893 | -208,118 (-21.91%) | 1.75% | $8 M | Nov 16, 2026 |
| 13 | ADAR1 Capital Management, LLC | 725,165 | +698,668 (+2636.78%) | 1.71% | $7 M | Nov 16, 2026 |
| 14 | Velan Capital Investment Management LP | 624,703 | +131,810 (+26.74%) | 1.47% | $6 M | Nov 16, 2026 |
| 15 | Marshall Wace, LLP | 612,310 | +606,510 (+10457.07%) | 1.44% | $6 M | Nov 13, 2026 |
| 16 | Pivotal bioVenture Partners Investment Advisor LLC | 611,446 | 0 (0.00%) | 1.44% | $6 M | Nov 13, 2026 |
| 17 | Blue Owl Capital Holdings LP | 556,371 | -173,558 (-23.78%) | 1.31% | $6 M | Nov 13, 2026 |
| 18 | Two Sigma Investments, LP | 516,022 | +507,024 (+5634.85%) | 1.22% | $5 M | Nov 16, 2026 |
| 19 | Geode Capital Management, LLC | 440,731 | +38,680 (+9.62%) | 1.04% | $4 M | Nov 6, 2026 |
| 20 | Point72 Asset Management, L.P. | 426,261 | New | 1.00% | $4 M | Nov 16, 2026 |
| 21 | Millennium Management LLC | 423,678 | +294,837 (+228.84%) | 1.00% | $4 M | Nov 16, 2026 |
| 22 | Capital World Investors | 415,760 | +30 (+0.01%) | 0.98% | $4 M | Nov 12, 2026 |
| 23 | Vanguard Capital Management LLC | 396,076 | -388,074 (-49.49%) | 0.93% | $4 M | Nov 13, 2026 |
| 24 | Trexquant Investment LP | 363,736 | +299,944 (+470.19%) | 0.86% | $4 M | Nov 16, 2026 |
| 25 | State Street Corp | 313,586 | -538,564 (-63.20%) | 0.74% | $3 M | Nov 12, 2026 |
Show all 98: investors 26 to 98
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Lazard Asset Management LLC | 263,905 | +183,823 (+229.54%) | 0.62% | $3 M | Nov 16, 2026 |
| 27 | BNP Paribas Financial Markets | 245,219 | +174,735 (+247.91%) | 0.58% | $2 M | Nov 12, 2026 |
| 28 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 170,862 | 0 (0.00%) | 0.40% | $2 M | Nov 13, 2026 |
| 29 | DAFNA Capital Management LLC | 155,579 | -15,427 (-9.02%) | 0.37% | $2 M | Nov 16, 2026 |
| 30 | TD Asset Management Inc | 140,888 | +86,362 (+158.39%) | 0.33% | $1 M | Nov 13, 2026 |
| 31 | Northern Trust Corp | 129,095 | +12,443 (+10.67%) | 0.30% | $1 M | Nov 16, 2026 |
| 32 | Charles Schwab Investment Management Inc | 122,473 | -14,345 (-10.48%) | 0.29% | $1 M | Nov 16, 2026 |
| 33 | Vanguard Portfolio Management LLC | 120,871 | +24,110 (+24.92%) | 0.28% | $1 M | Nov 13, 2026 |
| 34 | Superstring Capital Management LP | 118,304 | -7,128 (-5.68%) | 0.28% | $1 M | Nov 16, 2026 |
| 35 | Vanguard Fiduciary Trust Co | 116,464 | -6,671 (-5.42%) | 0.27% | $1 M | Nov 13, 2026 |
| 36 | UBS Group AG | 102,232 | -19,796 (-16.22%) | 0.24% | $1 M | Nov 10, 2026 |
| 37 | Barclays PLC | 85,813 | +72,838 (+561.37%) | 0.20% | $1 M | Nov 6, 2026 |
| 38 | Citadel Advisors LLC | 85,475 | +59,724 (+231.93%) | 0.20% | $1 M | Nov 16, 2026 |
| 39 | HRT Financial LP | 83,737 | +31,754 (+61.09%) | 0.20% | $1 M | Nov 13, 2026 |
| 40 | Manufacturers Life Insurance Company, The | 83,274 | +76,234 (+1082.87%) | 0.20% | $1 M | Nov 13, 2026 |
| 41 | Quadrature Capital Ltd | 74,485 | New | 0.18% | $1 M | Nov 13, 2026 |
| 42 | XTX Topco Ltd | 63,396 | +38,477 (+154.41%) | 0.15% | $1 M | Nov 16, 2026 |
| 43 | Morgan Stanley | 60,716 | +22,412 (+58.51%) | 0.14% | $1 M | Nov 13, 2026 |
| 44 | Citigroup Inc | 59,173 | +42,122 (+247.04%) | 0.14% | $1 M | Nov 4, 2026 |
| 45 | Jump Financial, LLC | 58,461 | +33,239 (+131.79%) | 0.14% | $1 M | Nov 13, 2026 |
| 46 | Schonfeld Strategic Advisors LLC | 54,016 | New | 0.13% | $1 M | Nov 16, 2026 |
| 47 | Nuveen, LLC | 30,957 | +13,036 (+72.74%) | 0.07% | $0 M | Nov 10, 2026 |
| 48 | Bank of New York Mellon Corp | 30,218 | -192 (-0.63%) | 0.07% | $0 M | Nov 5, 2026 |
| 49 | D. E. Shaw & Co., Inc. | 29,369 | New | 0.07% | $0 M | Nov 16, 2026 |
| 50 | Gsa Capital Partners LLP | 29,193 | New | 0.07% | $0 M | Nov 16, 2026 |
| 51 | HSBC Holdings PLC | 27,937 | New | 0.07% | $0 M | Nov 16, 2026 |
| 52 | Ghisallo Capital Management LLC | 20,000 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 53 | Engineers Gate Manager LP | 18,952 | New | 0.04% | $0 M | Nov 16, 2026 |
| 54 | Axq Capital, LP | 18,928 | New | 0.04% | $0 M | Nov 12, 2026 |
| 55 | Susquehanna International Group, LLP | 18,698 | New | 0.04% | $0 M | Nov 16, 2026 |
| 56 | Bank Of America Corp /de/ | 16,094 | -38,370 (-70.45%) | 0.04% | $0 M | Nov 16, 2026 |
| 57 | Alliancebernstein L.P. | 15,880 | New | 0.04% | $0 M | Nov 16, 2026 |
| 58 | Squarepoint Ops LLC | 15,735 | New | 0.04% | $0 M | Nov 9, 2026 |
| 59 | Rhumbline Advisers | 14,156 | -1,592 (-10.11%) | 0.03% | $0 M | Nov 10, 2026 |
| 60 | Market Street Wealth Management Advisors LLC | 14,124 | 0 (0.00%) | 0.03% | $0 M | Oct 9, 2026 |
| 61 | Jane Street Group, LLC | 13,286 | New | 0.03% | $0 M | Nov 12, 2026 |
| 62 | Jpmorgan Chase & Co | 11,823 | +7,491 (+172.92%) | 0.03% | $0 M | Nov 12, 2026 |
| 63 | Virtus Investment Advisers, LLC | 11,435 | -356 (-3.02%) | 0.03% | $0 M | Nov 12, 2026 |
| 64 | MA Private Wealth | 10,389 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 65 | LMR Partners LLP | 10,000 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 66 | Deutsche Bank AG\ | 9,019 | -1,307 (-12.66%) | 0.02% | $0 M | Nov 6, 2026 |
| 67 | Vanguard Global Advisers, LLC | 7,533 | -895 (-10.62%) | 0.02% | $0 M | Nov 13, 2026 |
| 68 | Russell Investments Group, Ltd. | 7,321 | +54 (+0.74%) | 0.02% | $0 M | Nov 6, 2026 |
| 69 | Tower Research Capital LLC (TRC) | 6,917 | +4,921 (+246.54%) | 0.02% | $0 M | Nov 16, 2026 |
| 70 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 6,200 | -211 (-3.29%) | 0.01% | $0 M | Nov 16, 2026 |
| 71 | New York State Common Retirement Fund | 5,300 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 72 | Wells Fargo & Company/mn | 3,768 | -5,651 (-60.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 73 | Global Retirement Partners, LLC | 3,367 | +3,304 (+5244.44%) | 0.01% | $0 M | Nov 10, 2026 |
| 74 | Police & Firemen's Retirement System of New Jersey | 2,300 | -3,191 (-58.11%) | 0.01% | $0 M | Nov 9, 2026 |
| 75 | SBI Securities Co., Ltd. | 1,709 | +549 (+47.33%) | 0.00% | $0 M | Oct 22, 2026 |
| 76 | Simplex Trading, LLC | 1,456 | +918 (+170.63%) | 0.00% | $0 M | Nov 4, 2026 |
| 77 | Caitong International Asset Management Co., Ltd | 1,265 | +715 (+130.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 78 | Legal & General Group Plc | 1,033 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 79 | Ameritas Investment Partners, Inc. | 946 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 80 | Royal Bank Of Canada | 696 | +222 (+46.84%) | 0.00% | $0 M | Nov 16, 2026 |
| 81 | Fifth Third Bancorp | 574 | New | 0.00% | $0 M | Nov 5, 2026 |
| 82 | Jones Financial Companies Lllp | 409 | New | 0.00% | $0 M | Nov 13, 2026 |
| 83 | Osaic Holdings, Inc. | 375 | -1,523 (-80.24%) | 0.00% | $0 M | Nov 12, 2026 |
| 84 | Sterling Capital Management LLC | 331 | +275 (+491.07%) | 0.00% | $0 M | Oct 22, 2026 |
| 85 | PNC Financial Services Group, Inc. | 316 | +222 (+236.17%) | 0.00% | $0 M | Nov 6, 2026 |
| 86 | Farther Finance Advisors, LLC | 282 | +162 (+135.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 87 | State of Wyoming | 238 | -123 (-34.07%) | 0.00% | $0 M | Oct 28, 2026 |
| 88 | GAMMA Investing LLC | 190 | +67 (+54.47%) | 0.00% | $0 M | Oct 8, 2026 |
| 89 | California State Teachers Retirement System | 144 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 90 | Fortitude Family Office, LLC | 76 | New | 0.00% | $0 M | Oct 14, 2026 |
| 91 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 42 | New | 0.00% | $0 M | Nov 16, 2026 |
| 92 | Arax Advisory Partners | 18 | -15 (-45.45%) | 0.00% | $0 M | Nov 12, 2026 |
| 93 | EverSource Wealth Advisors, LLC | 18 | +10 (+125.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 94 | CoreCap Advisors, LLC | 9 | New | 0.00% | $0 M | Oct 8, 2026 |
| 95 | Covestor Ltd | 9 | -7 (-43.75%) | 0.00% | $0 M | Oct 30, 2026 |
| 96 | Ascentis Wealth Management, LLC | 8 | New | 0.00% | $0 M | Nov 3, 2026 |
| 97 | Allworth Financial LP | 2 | -5 (-71.43%) | 0.00% | $0 M | Nov 17, 2026 |
| 98 | Silver Grove Financial Group, Inc. | 2 | New | 0.00% | $0 M | Nov 5, 2026 |
Mutual funds holding MapLight Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc. | 625,046 | $22 M | 1.5% | 0.24% | −0.1% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc. | 605,601 | $22 M | 1.5% | 0.21% | −2.5% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 552,279 | $20 M | 1.3% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 498,428 | $18 M | 1.2% | 0.17% | new | Jun 30, 2026 |
| 🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc | 404,389 | $14 M | 0.99% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc. | 402,792 | $14 M | 0.98% | 0.15% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 398,809 | $14 M | 0.97% | 0.10% | +750% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc. | 342,343 | $12 M | 0.84% | 0.24% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 267,770 | $10 M | 0.65% | 0.01% | −42% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 216,312 | $8 M | 0.53% | <0.01% | −4.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC | 406,402 | $5 M | 0.99% | 0.07% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC | 263,529 | $3 M | 0.64% | 0.07% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 103,544 | $3 M | 0.25% | <0.01% | +27% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 83,819 | $3 M | 0.20% | 0.02% | +1.3% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 99,384 | $3 M | 0.24% | 0.02% | +19% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 94,698 | $3 M | 0.23% | 0.01% | +26% | May 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 202,900 | $3 M | 0.50% | 0.12% | no change | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Mid Cap ETFT. Rowe Price Associates, Inc. | 63,511 | $2 M | 0.16% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC | 138,400 | $2 M | 0.34% | 0.11% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 131,368 | $2 M | 0.32% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC | 45,267 | $2 M | 0.11% | 0.14% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Value PortfolioMason Street Advisors, LLC | 42,858 | $2 M | 0.10% | 0.23% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 42,357 | $2 M | 0.10% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 114,415 | $1 M | 0.28% | <0.01% | −40% | Jul 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 50,257 | $1 M | 0.12% | 0.02% | new | May 29, 2026 |
| 🇺🇸 Small-Cap Value FundBridgeway Capital Management, LLC | 35,000 | $1 M | 0.09% | 0.37% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 34,702 | $1 M | 0.08% | 0.08% | −29% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity FundT. Rowe Price Associates, Inc. | 32,604 | $1 M | 0.08% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 39,111 | $1 M | 0.10% | <0.01% | +23% | May 31, 2026 |
| 🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc. | 29,135 | $1 M | 0.07% | 0.14% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 30,430 | $1 M | 0.07% | <0.01% | +22% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 29,346 | $1 M | 0.07% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 21,112 | $1 M | 0.05% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 19,495 | $1 M | 0.05% | 0.01% | −32% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Moderate Growth Allocation FundT. Rowe Price Associates, Inc. | 23,178 | $1 M | 0.06% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC | 23,000 | $1 M | 0.06% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 15,384 | $1 M | 0.04% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 13,151 | $0 M | 0.03% | 0.01% | −7.0% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 11,760 | $0 M | 0.03% | 0.01% | −44% | Jun 30, 2026 |
| 🇺🇸 SMALLCAP World FundCapital Research and Management Company | 11,341 | $0 M | 0.03% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 11,224 | $0 M | 0.03% | <0.01% | −86% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 25,379 | $0 M | 0.06% | <0.01% | −40% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 8,606 | $0 M | 0.02% | 0.02% | +11% | Jun 30, 2026 |
| 🇺🇸 Small Company Value TrustJohn Hancock Variable Trust Advisers LLC | 8,524 | $0 M | 0.02% | 0.20% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 10,329 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 8,330 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 9,486 | $0 M | 0.02% | 0.02% | +17% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 7,297 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 7,200 | $0 M | 0.02% | <0.01% | +9.1% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Moderate Allocation FundT. Rowe Price Associates, Inc. | 7,636 | $0 M | 0.02% | 0.01% | −8.0% | May 31, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 16,937 | $0 M | 0.04% | 0.04% | new | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 7,465 | $0 M | 0.02% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 5,900 | $0 M | 0.01% | <0.01% | −42% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 7,044 | $0 M | 0.02% | 0.02% | +21% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 5,082 | $0 M | 0.01% | 0.01% | −47% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 13,865 | $0 M | 0.03% | <0.01% | −40% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 4,526 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 4,464 | $0 M | 0.01% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 11,837 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Conservative Allocation FundT. Rowe Price Associates, Inc. | 5,103 | $0 M | 0.01% | <0.01% | −5.9% | May 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 4,064 | $0 M | <0.01% | 0.01% | −31% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 4,040 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 4,040 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 3,895 | $0 M | <0.01% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 10,157 | $0 M | 0.02% | <0.01% | −1.7% | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 3,632 | $0 M | <0.01% | 0.01% | −37% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 4,414 | $0 M | 0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 3,476 | $0 M | <0.01% | <0.01% | +7984% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 3,800 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 3,036 | $0 M | <0.01% | 0.01% | −45% | Jun 30, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 2,976 | $0 M | <0.01% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 2,576 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 6,932 | $0 M | 0.02% | <0.01% | −0.1% | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,348 | $0 M | <0.01% | 0.01% | −40% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,340 | $0 M | <0.01% | 0.04% | −32% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 2,215 | $0 M | <0.01% | 0.01% | −38% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 2,041 | $0 M | <0.01% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 1,907 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 4,990 | $0 M | 0.01% | <0.01% | −41% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 1,787 | $0 M | <0.01% | <0.01% | −84% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,639 | $0 M | <0.01% | 0.01% | −40% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 1,617 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 1,590 | $0 M | <0.01% | 0.01% | −26% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 1,831 | $0 M | <0.01% | <0.01% | +38% | May 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 1,427 | $0 M | <0.01% | 0.01% | −31% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,282 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,221 | $0 M | <0.01% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 2,892 | $0 M | <0.01% | <0.01% | −4.0% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 946 | $0 M | <0.01% | 0.01% | −31% | Jun 30, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 929 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Moderate Allocation PortfolioT. Rowe Price Associates, Inc. | 895 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 834 | $0 M | <0.01% | 0.01% | −38% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 815 | $0 M | <0.01% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 910 | $0 M | <0.01% | 0.01% | +24% | May 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 1,888 | $0 M | <0.01% | <0.01% | −29% | Jul 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 674 | $0 M | <0.01% | <0.01% | −3.2% | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 633 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,677 | $0 M | <0.01% | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 723 | $0 M | <0.01% | <0.01% | −31% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 712 | $0 M | <0.01% | <0.01% | −32% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at MapLight Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Christopher A. KroegerChief Executive Officer, Director | Sell | -73,691 | $8.080 | $595 K | 1.20 M | Form 4 |
| filed | Jonathan GillisCAO and Interim CFO | Sell | -10,167 | $8.080 | $82 K | 142,315 | Form 4 |
| filed | James Woodruff LillieChief Scientific Officer | Sell | -11,513 | $8.080 | $93 K | 198,597 | Form 4 |
| filed | Kristopher HansonGeneral Counsel | Sell | -9,020 | $8.080 | $73 K | 128,024 | Form 4 |
| filed | Erin Pennock FoffChief Medical Officer | Sell | -15,355 | $8.080 | $124 K | 296,906 | Form 4 |
| filed | Anatol KreitzerChief Discovery Officer | Sell | -12,248 | $7.840 | $96 K | 168,678 | Form 4 |
| filed | Kristopher HansonGeneral Counsel | Sell10b5-1 plan | -16,509 | $11.67 | $193 K | 137,044 | Form 4 |
| filed | James Woodruff LillieChief Scientific Officer | Grant or award | +7,730 | — | — | 210,110 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: MapLight Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: registered (S-1), not yet priced · IPO calendar
Stock splits: 1-for-16.81 reverse split
Fails to deliver
- : 165 shares at $7.97
- : 42,158 shares at $8.16
- : 3,314 shares at $7.81
- : 43 shares at $13.15
- : 3,752 shares at $13.71
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
MapLight Therapeutics, Inc. scorecard#
Passes 1 of the 4 checks that could be worked out. Fiscal year 2025; market cap of Sep 15, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-09-15, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-09-15, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-09-15, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-09-15, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-09-15, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-09-15, more than 60 days ago.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-18.56 vs -105.38Diluted EPS -18.56 in fiscal 2025 against -105.38 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$161 MNet income -$161 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-121.7%-121.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- ✓Short-term assets cover short-term liabilities20.0×Current ratio 20.00 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-09-15, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
MapLight Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 |
|---|---|---|---|
| Income statement | |||
| Research and development | 138+102%— | 69—— | |
| General and administrative | 31+113%— | 14—— | |
| Operating expenses | 169+104%— | 83—— | |
| Operating income | −169—— | −83—— | |
| Interest and finance income | 5.5+22.5%— | 4.5—— | |
| Other non-operating income (expense) | 7.9+47.8%— | 5.4—— | |
| Net income attributable to shareholders | −161—— | −78—— | |
| Earnings per share, basic | -18.56—— | -105.38—— | |
| Earnings per share, diluted | -18.56—— | -105.38—— | |
| Shares, weighted average (basic) | 8.7+1079%— | 0.7—— | |
| Shares, weighted average (diluted) | 8.7+1079%— | 0.7—— | |
| Balance sheet | |||
| Cash and cash equivalents | 47+22.2%9.7% | 38—27.9% | |
| Short-term investments | 258+266%53.9% | 71—51.5% | |
| Other current assets | 20+237%4.1% | 5.8—4.2% | |
| Current assets | 325+183%67.7% | 115—83.7% | |
| Property, plant and equipment | 1.1−9.3%0.2% | 1.2—0.9% | |
| Right-of-use (leased) assets | 5.5−13.6%1.1% | 6.4—4.6% | |
| Long-term investments | 148+1200%30.9% | 11—8.3% | |
| Total assets | 480+250%100% | 137—100% | |
| Accounts payable | 3.3+72.0%0.7% | 1.9—1.4% | |
| Current liabilities | 16+1.9%3.4% | 16—11.6% | |
| Lease liabilities (non-current) | 4.9−15.3%1.0% | 5.8—4.2% | |
| Non-current liabilities | — | 5.8—4.2% | |
| Total liabilities | 21−2.7%4.4% | 22—15.9% | |
| Retained earnings | −361—−75.2% | −199—−146% | |
| Shareholders' equity | 458—95.6% | −194—−141% | |
| Total liabilities and equity | 480+250%100% | 137—100% | |
| Shares outstanding | 44+5683%— | 0.8—— | |
| Cash-flow statement | |||
| Share-based compensation | 36+3234%— | 1.1—— | |
| Cash from operating activities | −138—— | −79—— | |
| Capital expenditure | −0.5—— | −0.8—— | |
| Cash from investing activities | −323—— | −81—— | |
| Cash from financing activities | 470+298%— | 118—— | |
| Report | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Research and development | 199—— | 53—— | 54—— | 65*—— | 27—— | |
| General and administrative | 44—— | 10—— | 11—— | 19*—— | 4.4—— | |
| Operating expenses | 243—— | 64—— | 65—— | 83*—— | 31—— | |
| Operating income | −243—— | −64—— | −65—— | −83*—— | −31—— | |
| Interest and finance income | 8.8—— | 2.3—— | 2.5—— | 2.5*—— | 1.5—— | |
| Other non-operating income (expense) | 8.3—— | 1.0—— | 1.4—— | 3.8*—— | 2.1—— | |
| Net income attributable to shareholders | −230—— | −60—— | −61—— | −80*—— | −29—— | |
| Earnings per share, basic | — | -1.32—— | -1.34—— | — | -37.18—— | |
| Earnings per share, diluted | — | -1.32—— | -1.34—— | — | -37.18—— | |
| Shares, weighted average (basic) | 45—— | 45—— | 45—— | — | 0.8—— | |
| Shares, weighted average (diluted) | 45—— | 45—— | 45—— | — | 0.8—— | |
| Balance sheet | ||||||
| Cash and cash equivalents | 72—19.4% | 72—19.4% | 56—13.3% | 47—9.7% | 64—24.9% | |
| Short-term investments | 233—63.3% | 233—63.3% | 254—60.7% | 258—53.9% | 163—63.4% | |
| Other current assets | 14—3.8% | 14—3.8% | 17—4.1% | 20—4.1% | 18—7.1% | |
| Current assets | 319—86.5% | 319—86.5% | 327—78.1% | 325—67.7% | 245—95.4% | |
| Property, plant and equipment | 0.8—0.2% | 0.8—0.2% | 1.0—0.2% | 1.1—0.2% | 0.9—0.3% | |
| Right-of-use (leased) assets | 1.7—0.5% | 1.7—0.5% | 5.3—1.3% | 5.5—1.1% | 5.7—2.2% | |
| Long-term investments | 47—12.7% | 47—12.7% | 85—20.3% | 148—30.9% | — | |
| Total assets | 368—100% | 368—100% | 419—100% | 480—100% | 257—100% | |
| Accounts payable | 2.1—0.6% | 2.1—0.6% | 3.2—0.8% | 3.3—0.7% | 2.4—1.0% | |
| Current liabilities | 19—5.2% | 19—5.2% | 14—3.4% | 16—3.4% | 19—7.2% | |
| Lease liabilities (non-current) | 0.8—0.2% | 0.8—0.2% | 4.7—1.1% | 4.9—1.0% | 5.1—2.0% | |
| Non-current liabilities | — | — | — | — | 5.1—2.0% | |
| Total liabilities | 20—5.4% | 20—5.4% | 19—4.5% | 21—4.4% | 24—9.2% | |
| Retained earnings | −481—−131% | −481—−131% | −421—−101% | −361—−75.2% | −281—−109% | |
| Shareholders' equity | 348—94.6% | 348—94.6% | 400—95.5% | 458—95.6% | −274—−107% | |
| Total liabilities and equity | 368—100% | 368—100% | 419—100% | 480—100% | 257—100% | |
| Shares outstanding | 45—— | 45—— | 45—— | 44—— | 0.8—— | |
| Cash-flow statement | ||||||
| Share-based compensation | 54—— | 8.6—— | 9.6—— | 36*—— | 0.1—— | |
| Cash from operating activities | — | −45*—— | −51—— | −47*—— | — | |
| Capital expenditure | — | −0.0*—— | −0.0—— | −0.4*—— | — | |
| Cash from investing activities | — | 61*—— | 67—— | −243*—— | — | |
| Cash from financing activities | — | 0.1*—— | −6.9—— | 272*—— | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at MapLight Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Material agreementUnregistered share saleResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Unregistered share saleBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 13, 2026
Acquisitions and funding#
6 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2025 | $188 M | No. 6 | $50 to $250 million | 19 | equity | SEC |
| Jul 2023 | $105 M | No. 5 | $50 to $250 million | 12 | equity | SEC |
| Oct 2022 | $12 M | No. 4 | $10 to $50 million | 1 | equity | SEC |
| Feb 2021 | $30 M | No. 3 | $10 to $50 million | 2 | equity | SEC |
| Aug 2019 | $16 M | No. 2 | $10 to $50 million | 2 | equity | SEC |
| Feb 2019 | $5 M | No. 1 | $2 to $10 million | 2 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at MapLight Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $160 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Scientist, Formulation DevelopmentChemists | 1 | $160 K |
Where: San Bruno, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $160 K | 1 |
| FY2024 | 1 | 1 | $400 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as MapLight Therapeutics, Inc.
Discuss MapLight Therapeutics, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Insider trading in October 2026automatic update · Oct 31, 2026
Directors and officers of MapLight Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 6 insiders sold shares worth about $1,063,572 in 6 trades. Awards, option exercises and shares withheld for tax are not counted.
- Mutual funds: 117 funds hold $211 millionautomatic update · Jul 31, 2026
117 mutual funds in 1 country hold shares of MapLight Therapeutics, Inc. worth $211 million, about 16.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 52 funds added shares and 49 sold; on balance they bought $75 million. Share splits are not counted as trading.
How MapLight Therapeutics, Inc. compares in Biotechnology
- Market cap$558 M · higher than 60% of 726
- Price / book1.2× · lower than 74% of 534
- FCF yield-24.8% · higher than 39% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| MapLight Therapeutics, Inc.🇺🇸 | $558 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Surrozen, Inc.$562 M
- Zhejiang Orient Gene Biotech Co., Ltd$553 M
- Arvinas, Inc.$544 M
- Entera Bio Ltd.$543 M
- Oneness Biotech Co., Ltd.$577 M
- Contineum Therapeutics, Inc.$534 M
Sources and freshness
- Market cap:
- Sep 15, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at MapLight Therapeutics, Inc.? Verify and update this profile — free
Show MapLight Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.